Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study

BACKGROUND: No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis treatment. OBJECTIVE: Determine treatment durability of cladribine tablets beyond 2 years considering the variable bridging interval of 0.1–116.0 weeks between CLARIT...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannoni, Gavin, Singer, Barry A, Issard, Delphine, Jack, Dominic, Vermersch, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189728/
https://www.ncbi.nlm.nih.gov/pubmed/34634968
http://dx.doi.org/10.1177/13524585211049392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189728/
https://www.ncbi.nlm.nih.gov/pubmed/34634968
http://dx.doi.org/10.1177/13524585211049392

Ejemplares similares